Back to results
US 10,695,419 B2Granted
Human cytomegalovirus vaccine
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Shinu John
Life of this patent
Estimating the term…
Abstract
The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Claims24
A human cytomegalovirus (hCMV) vaccine comprising:
- i) at least one RNA polynucleotide having one or more open reading frames encoding hCMV antigenic polypeptides gH, gL, UL128, UL130, and UL131A;
- ii) an RNA polynucleotide having an open reading frame encoding hCMV antigenic polypeptide gB;
- iii) an RNA polynucleotide having an open reading frame encoding hCMV antigenic polypeptide pp65, and
- iv) a pharmaceutically acceptable carrier or excipient,
- wherein the RNA polynucleotides of (i)-(iii) are formulated in at least one lipid nanoparticle that comprises a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid, in an effective amount to induce an immune response in a subject administered at least one dose of the vaccine.
2 more elements
A human cytomegalovirus (hCMV) vaccine comprising:
- (a) at least one RNA polynucleotide comprising nucleotides 46-2437 of SEQ ID NO:
- 189, (b) at least one RNA polynucleotide comprising nucleotides 46-1045 of SEQ ID NO:
- 190, (c) at least one RNA polynucleotide comprising nucleotides 46-724 of SEQ ID NO:
- 191, (d) at least one RNA polynucleotide comprising an nucleotides 46-853 of SEQ ID NO:
- 172, (e) at least one RNA polynucleotide comprising nucleotides 46-598 of SEQ ID NO:
- 193, (f) at least one RNA polynucleotide comprising nucleotides 46-2932 of SEQ ID NO:
- 162, and (g) at least one RNA polynucleotide encoded by SEQ ID NO:
- 92,
- wherein each of the RNA polynucleotides of (a)-(g) are mRNA polynucleotides,
- wherein each of the RNA polynucleotides of (a)-(f) further comprises a polyA tail, and
- wherein the polynucleotide of (g) further comprises a 5′UTR encoded by SEQ ID NO:
- 146, a 3′UTR encoded by SEQ ID NO:
- 147, and a polyA tail.
10 more elements
A human cytomegalovirus (hCMV) vaccine comprising:
- (a) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO:
- 58, (b) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO:
- 62, (c) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO:
- 60, (d) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO:
- 15, (e) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO:
- 66, (f) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO:
- 86, and (g) at least one RNA polynucleotide encoded by a DNA polynucleotide of SEQ ID NO:
- 92,
- wherein each of the RNA polynucleotides of (a)-(g) are mRNA polynucleotides,
- wherein each of the RNA polynucleotides of (a)-(f) comprises a polyA tail, and wherein the polynucleotide of (g) comprises a polyA tail and further comprises a 5′UTR encoded by SEQ ID NO:
- 146 and a 3′UTR encoded by SEQ ID NO:
- 147.
9 more elements
Dependencies are inferred from the claim text.